Filing Flows › Comparisons › SMTI vs MYO
Sanara MedTech vs Myomo: SMTI and MYO compared
Sanara MedTech is the larger company: $28.1M of revenue in its latest quarter (Q2 2026) against $11.7M for Myomo (Q2 2026). Myomo is growing faster (+21% against +9% a year earlier). Sanara MedTech is more profitable, with an operating margin of 6.3% against -19.3%.
Where the money goes: SMTI and MYO
Sanara MedTech (SMTI) · Q2 2026
Sanara MedTech, Q2 2026: revenue $28.1M (+9% year over year), operating margin 6.3%, net loss $453K, operating cash flow $2.0M. The chart follows the revenue to costs, profit and cash.
Myomo (MYO) · Q2 2026
Myomo, Q2 2026: revenue $11.7M (+21% year over year), operating margin -19.3%, net loss $4.0M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Sanara MedTech (SMTI) | Myomo (MYO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $28.1M | $11.7M |
| Revenue growth, Y/Y | +9% | +21% |
| Operating margin | 6.3% | -19.3% |
| Net earnings | −$453K | −$4.0M |
| Net margin | -1.6% | -34.4% |
| Operating cash flow | $2.0M | −$1.9M |
| Free cash flow | $2.0M | — |
| Market value | $304M | — |
| P/E | 7.0× | — |
| Analysts’ mean target | $35.00 | — |
Where the revenue comes from
Sanara MedTech
- Soft Tissue Repair Products: $25.2M (90%)
- Bone Fusion Products: $2.9M (10%)
Questions
Which is bigger, Sanara MedTech or Myomo?
Sanara MedTech is the larger company: $28.1M of revenue in its latest quarter (Q2 2026) against $11.7M for Myomo (Q2 2026).
Is Sanara MedTech or Myomo growing faster?
Myomo is growing faster (+21% against +9% a year earlier).
Which is more profitable, Sanara MedTech or Myomo?
Sanara MedTech is more profitable, with an operating margin of 6.3% against -19.3%.
More: Sanara MedTech earnings · how Sanara MedTech makes money · Myomo earnings · how Myomo makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Aug 5, 2026). Fiscal quarters can end on different dates. Not investment advice.